Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0MNGYS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-TM4SF1 antibody |
|||||
| Antigen Name | TM4SF1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AGX101 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients have histologically confirmed advanced/metastatic solid tumors refractory to standard therapy, ECOG 0-1, adequate organ function, and effective contraception. Exclusions include untreated CNS metastases, uncontrolled infections, unresolved Grade ≥2 AEs (except neuropathy/endocrine irAEs), major recent surgery/radiotherapy, life-threatening comorbidities, active infections, pregnancy, or recent use of CYP3A modulators. Colorectal cancer/NSCLC with squamous histology requires sponsor approval.
Click to Show/Hide
|
||||
| Administration Dosage |
Experimental: Dose Escalation Phase AGX-101, initial 90-minute IV infusion, second 60-minute IV infusion and 30 minute subsequent IV infusions on Day 1 of every 3, 6 or 9-week cycle in Dose Escalation Phase. Dose escalation will be carried out in sequential cohorts of escalating doses, with an expansion cohort in advanced angiosarcoma.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06440005 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients with Unresectable, Locally Advanced, or Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The study evaluates the maximum tolerated dose (MTD) of AGX101 and dose-limiting toxicities (DLTs) over 21 days post-dose (Day 1-Day 21). Adverse events will be assessed for incidence, severity, and duration from screening through treatment end (approx. 6 months up to 3 years).
|
||||
| Other Endpoint |
Pharmacokinetic parameters include terminal elimination half-life, AUC, and Cmax over 22 days (Day 1-Day 22). ADA levels will be measured for approx. 6 months up to 3 years. Efficacy assessments involve ORR, DoR, DCR, PFS, treatment duration, and overall survival per RECIST v1.1.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.60% | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.40% | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.50% | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Breast ductal cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.60% | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Breast ductal cancer CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.10% | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither CALU-3 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Lung adenocarcinoma CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | Calu-3 cells | CVCL_0609 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ solid tumor cell lines.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ cell lines.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
References